A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #995

Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures.

Radwańska P, Olkiewicz M, Piera L, et al. Pharmacological reports. 2026.
Weak / noneIn vitroMentions: Kisspeptin

Editor's note

A cell-culture study, not a human or animal trial, so findings speak only to mechanism. Kisspeptin-10 was the direct subject and showed a dose-dependent, receptor-dependent signal associated with cardiac extracellular-matrix remodeling that would need in vivo confirmation.

Plain-language abstract

In cultured human heart fibroblast cells, kisspeptin-10 increased production of extracellular-matrix components through GPR54 and FAK signaling.